Figure 1.

Course of specific humoral and cellular immunity in four patients with chronic kidney disease infected with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and receiving convalescent plasma treatment. Antibodies were determined by an S1 specific immunoglobulin G (IgG) enzyme‐linked immunosorbent assay (Euroimmun) and by cell‐culture based neutralization assay (NT titer). Cellular responses were analyzed by an interferon‐gamma (IFN‐γ) ELISpot assay, using peptide pools of the S1/S2, S1, and M protein and an S1 protein antigen as specific stimuli (depicted as S1/S2, S1, M, and S ELI). We here present data on two kidney transplant recipients (RTX01, RTX02) and two patients on hemodialysis (HD01, HD02) and compared their immune responses with those of the corresponding donors of convalescent plasma (CP; shaded area). SARS‐CoV‐2‐specific antibody data (IgG ratio and NT titer) are given on the left Y‐axis and ELISpot data on the right one. Horizontal dashed lines represent the cut‐off values for positive reactions (IgG ratio of 1.1 and NT titer of 1:20). Vertical dotted lines indicate the time points of convalescent plasma applications (CP1, CP2, and CP3). Related data points are connected. PBMC, peripheral blood mononuclear cells